Shape Memory Medical Receives ANVISA Authorization for IMPEDE Embolization Plug Family in Brazil

Shape Memory Medical has announced that Brazil’s national health surveillance agency, ANVISA (Agência Nacional de Vigilância Sanitária), has granted authorization for the IMPEDE Embolization Plug, the IMPEDE-FX Embolization Plug, and the IMPEDE-FX RapidFill. The approval process was supported by Biomedical, which acts as Shape Memory Medical’s Brazilian registration holder for its peripheral embolization product line.
In Brazil, the three devices are indicated to obstruct or reduce the rate of blood flow in the peripheral vasculature. The IMPEDE and IMPEDE-FX Embolization Plugs are available in three sizes, with the largest device offering an expanded diameter of 12 mm and an embolic volume capacity of 1.25 mL. The IMPEDE-FX RapidFill offers up to 6.25 mL of expanded embolic volume, providing a versatile solution for embolization procedures across a wide range of peripheral vessels. Multiple peer-reviewed studies have demonstrated the safety and effectiveness of the company’s shape memory polymer solutions in peripheral embolization.
The IMPEDE product family incorporates Shape Memory Medical’s shape memory polymer, a radiolucent and highly porous material designed for catheter-based delivery. Once delivered through a standard catheter, the polymer expands upon exposure to body temperature and blood, returning to its pre-set shape and creating a conformable scaffold that encourages thrombus formation without exerting untoward radial force on vasculature, supporting efficient and long-lasting vessel occlusion.
Ted Ruppel, President and CEO of Shape Memory Medical, said Brazil represents one of the largest and fastest-growing endovascular markets in Latin America, with an estimated 30,000 embolization procedures performed annually and projected market growth exceeding 10%, making this an important milestone for the company. Ruppel noted that together with Biomedical, Shape Memory Medical looks forward to bringing its shape memory polymer solution to physicians treating peripheral vascular disease while continuing to expand its presence in the region.
Bernardo Machado, Chief Executive Officer of Biomedical, said the company has already seen strong interest from Brazil’s endovascular community as it prepares to introduce this innovative shape memory polymer technology. Machado noted that adding the IMPEDE product family enhances Biomedical’s vascular portfolio, helping broaden its footprint and growth opportunities within the embolization therapy space.
